UNITED THERAPEUTICS (UTHR) director Nilda Mesa sells 258 common shares

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Nilda Mesa sold shares in an open‑market transaction. On this trade, Mesa sold 258 shares of common stock at a price of $581.935 per share. After the sale, Mesa directly owned 5,028 shares of UNITED THERAPEUTICS common stock.

Insider Trade Summary

Net Seller: 258 shares ($150,139)

Net Sell 1 txn

Insider Mesa Nilda

Role null

Sold 258 shs ($150K)

Type	Security	Shares	Price	Value
Sale	Common Stock	258	$581.935	$150K

Holdings After Transaction: Common Stock — 5,028 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 258 shares Sale price per share: $581.935 per share Shares owned after sale: 5,028 shares

3 metrics

Shares sold 258 shares Common stock sold on May 12, 2026

Sale price per share $581.935 per share Open-market sale of common stock

Shares owned after sale 5,028 shares Direct holdings following transaction

Key Terms

Form 4, open-market sale, direct ownership

3 terms

Form 4 regulatory

"The Form 4 classifies it with code “S” and describes it as an open-market or private sale"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"She sold 258 shares on May 12, 2026, and the transaction was coded as an open-market or private sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

direct ownership financial

"The filing shows Nilda Mesa’s remaining 5,028 UNITED THERAPEUTICS shares as directly owned"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mesa Nilda

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		S		258	D	$581.935	5,028	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) director Nilda Mesa report?

Director Nilda Mesa reported an open-market sale of UNITED THERAPEUTICS common stock. She sold 258 shares on May 12, 2026, and the transaction was coded as an open-market or private sale on the Form 4 filing.

How many UNITED THERAPEUTICS (UTHR) shares did Nilda Mesa sell and at what price?

Nilda Mesa sold 258 shares of UNITED THERAPEUTICS common stock. The reported sale price was $581.935 per share, indicating a single open-market sale transaction according to the Form 4 insider trading report.

How many UNITED THERAPEUTICS (UTHR) shares does Nilda Mesa hold after this transaction?

After the reported sale, Nilda Mesa directly holds 5,028 shares of UNITED THERAPEUTICS common stock. This post-transaction balance is disclosed in the Form 4 as the total shares owned following the open-market sale.

Was Nilda Mesa’s UNITED THERAPEUTICS (UTHR) transaction a buy or a sell?

The transaction was a sell. The Form 4 classifies it with code “S” and describes it as an open-market or private sale of common stock, reflecting a disposition rather than a purchase of UNITED THERAPEUTICS shares.

Does Nilda Mesa hold UNITED THERAPEUTICS (UTHR) shares directly or indirectly after the sale?

The filing shows Nilda Mesa’s remaining 5,028 UNITED THERAPEUTICS shares as directly owned. The ownership code is listed as “D,” indicating direct ownership of the common stock following the reported open-market sale.